Merck(MRK) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total company revenues for Q4 2025 were $16.4 billion, reflecting a 5% increase, or 4% excluding foreign exchange impact [12] - Earnings per share (EPS) were reported at $2.04, with guidance for 2026 EPS expected to be between $5.00 and $5.15 [19][20] Business Line Data and Key Metrics Changes - Oncology sales, including Keytruda, increased by 5% to $8.4 billion, driven by strong demand in earlier-stage cancers and metastatic indications [13] - Sales of Welireg increased by 37% to $220 million, primarily due to increased use in advanced renal cell carcinoma [15] - Gardasil sales decreased by 35% to $1 billion, attributed to lower demand in China and Japan [15] - The animal health business grew by 6%, with livestock sales increasing by 9% [18] Market Data and Key Metrics Changes - In the U.S., Keytruda's growth was negatively impacted by approximately $200 million due to the timing of purchases [14] - Sales of Capvaxive reached $279 million, driven by demand from retail pharmacies and increased seasonal immunization activity [15] - Winrevair achieved global sales of $467 million, reflecting strong demand for pulmonary arterial hypertension treatment [16] Company Strategy and Development Direction - The company aims to deliver transformative medicines and vaccines, with a focus on breakthrough science and innovation [4] - A significant commercial opportunity of over $70 billion is projected by the mid-2030s, bolstered by new product launches and acquisitions [5] - The company is committed to investing in its innovative pipeline and key growth drivers, with a focus on sustainable long-term value [12][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver sustainable growth post-Keytruda LOE, with a robust pipeline and strategic business development [5][21] - The company anticipates growth in 2026 driven by new product launches and continued strength in oncology and animal health, despite challenges from generic competition [21][22] Other Important Information - The company completed the acquisition of Cidara Therapeutics, enhancing its portfolio in infectious diseases [8][26] - The company expects to see significant growth in its animal health business, with projections to double by the mid-2030s [21] Q&A Session Summary Question: Can you elaborate on the CD388 asset and its potential? - Management highlighted the importance of robust data across multiple geographies and seasons for the ongoing trial, emphasizing the need for strong data to support future labeling [38][39] Question: Are there plans to explore sac-TMT in first-line settings? - Management indicated that they view sac-TMT as a potential best-in-class asset and have a robust program with multiple phase 3 studies planned [43][44] Question: How should the intellectual property runway for Keytruda be modeled? - Management clarified that while the compound patent expires in December 2028, there are additional patents extending to 2029, and they remain confident in defending these patents [48][49] Question: What is the significance of the dual regimen for HIV treatment? - Management emphasized the potential of Islatravir as a next-generation nucleoside analog, providing new options for patients and addressing unmet needs in HIV treatment [53][54] Question: What is the outlook for Merck's growth in the coming years? - Management expressed confidence in sustainable growth driven by a strong pipeline and significant commercial opportunities, despite challenges from LOEs [60][61]